• 1
    Lindstrom, T. M. and Robinson, W. H. (2010) Biomarkers for rheumatoid arthritis: making it personal. Scand. J. Clin. Lab. Invest. 70, 7984.
  • 2
    Bertero, M. T. and Caligaris-Cappio, F. (1997) Anemia of chronic disorders in systemic autoimmune diseases. Haematologica 82, 375381.
  • 3
    Bowman, S. J. (2002) Hematological manifestations of rheumatoid arthritis. Scand. J. Rheumatol. 31, 251259.
  • 4
    Kim, H.-R., Kim, K.-W., Yoon, S.-Y., Kim, S.-H., and Lee, S.-H. (2010) Serum Pro-hepcidin could reflect disease activity in patients with rheumatoid arthritis. J. Korean Med. Sci. 25, 348352.
  • 5
    Krause, A., Neitz, S., Magert, H. J., Schultz, A., Forssman, W. G., et al. (2000) A novel highly disulfide-bonded human peptide exhibits antimicrobial activity. FEBS Lett. 480,147150.
  • 6
    Park, C. H., Valone, E. V., Waring, A. J., and Ganz, T. (2001) Hepcidin, a urinary antimicrobial peptide synthesized by the liver. J. Biol. Chem. 276, 78067810.
  • 7
    Nemeth, E., Valore, E. V., Territo, M., Schiller, G., Lichtenstein, A., et al. (2003) Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101, 24612463.
  • 8
    Andrews, N. C. (2004) Anemia of inflammation. J. Clin. Invest. 113,12511253.
  • 9
    Nemeth, E., Rivera, S., Gabayan, V., Valore, E. V., and Ganz, T. (2004) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 113,12711275.
  • 10
    Nicolas, G., Chauvet, C., Viatte, L., Danan, J. L., Bigard, X., et al. (2002) The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J. Clin. Invest. 110, 10371044.
  • 11
    van Minkelen, R., de Visser, M. C. H., Houwing-Duistermaat, J. J., Vos, H. L., Bertina R. M., et al. (2007) Haplotypes of IL1B, IL1RN, IL1R1, and IL1R2 and the risk of venous thrombosis. Arterioscler. Thromb. Vasc. Biol. 27, 14861491.
  • 12
    Swellam, M., Mahmoud, M. S., Samy, N., and Gamal, A. A. (2010) Potential influence of interleukin-1 receptor antagonist gene polymorphism on knee osteoarthritis risk. Disease Markers 28, 299305.
  • 13
    Grover, S., Tandon, S., Misra, R., and Aggarwal, A. (2006) Interleukin-1 receptor antagonist gene polymorphism in patients with rheumatoid arthritis in India. Indian J. Med. Res. 123, 815820.
  • 14
    Blakemore, A. I. F., Tarlow, J. K., Cork, M. J., Goedon, C., Emery, P., et al. (1994) Interleukin 1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum. 37, 13801385.
  • 15
    Vencovsk, J., Jarosov, K., Ruzickov, S., Nemcova, D., Niederlova, J., et al. (2001) Higher frequency of allele 2 of the interleukin-1 receptor antagonist gene in patients with juvenile idiopathic arthritis. Arthritis Rheum. 44, 23872391.
  • 16
    Ruzickova, S., Senolt, L., Gatterova, J., Vencovsky, J., and Pavelka, K. (2008) The lack of correlation between the increased frequency of allele IL-1RN*2 of interleukin-1 receptor antagonist gene in Czech patients with knee osteoarthritis and the markers of cartilage degradation. Folia Biol. (Praha) 54, 115120.
  • 17
    Arnett, F. C., Edworthy, S. M., Bloch, D. A., McShane, D. J., Fries J. F., et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31, 315324.
  • 18
    Weiss, G. (2002) Pathogenesis and treatment of anaemia of chronic disease. Blood Rev. 16, 8796.
  • 19
    Ohashi, J., Naka, I., Doi, A., Patarapotikul, J., and Hananantachai, H., et al. (2005) A functional polymorphism in the IL1B gene promoter, IL-IB−31C>T, is not associated with cerebral malaria in Thailand. Malar. J. 4, 602608.
  • 20
    Coskun, M., Bacanli, A., Sallakci, N., Alpsoy, E., Yavuzer, U., et al. (2005) Specific interleukin-1 gene polymorphism in Turkish patients with Behcet's disease. Exp. Dermatol. 14, 124129.
  • 21
    Parmeet, K., Hemeant, K., and Rama, D. (2005) Ethically greatly influences the interleukin-1 gene cluster polymorphisms: a pilot study of a North Indian population, Asian Pacific J. Cancer Prev. 6, 541544.
  • 22
    Junge, G., Kyung, S., Seung-Yup, K., Seok, H., Young, M., et al. (2006) Relations between interleukin−1, its receptor antagonist gene polymorphism, and bone density in postmenopausal Korean women. J. Bone Miner. Metab. 2444, 10681071.
  • 23
    Rowan, A. D. (2001) Cartilage catabolism in arthritis: factors that influence homeostasis. Expert Rev. Mol. Med. 2001, 120;Availableat:
  • 24
    van Santen, S., van Dongen-Lases, E. C., de Vegt, F., Laarakkers, C. M. M., van Riel, P. L. C. M., et al. (2011) Hepcidin and hemoglobin content parameters in the diagnosis of iron deficiency in rheumatoid arthritis patients with anemia. Arthritis Rheum. 63, 36723680.
  • 25
    Ganz, T. (2005) Hepcidin a regulator of intestinal iron absorption and iron recycling by macrophages. Best Pract. Res. Clin. Haematol. 18, 171182.
  • 26
    Yamaji, S., Sharp, P., Ramesh, B., and Srai, S. K. (2004) Inhibition of iron transport across human intestinal epithelial cells by hepcidin. Blood 104, 21782180.
  • 27
    Rivera, S., Nemeth, E., Gabayan, V., Lopez, M. A., Farshidi, D., et al. (2005) Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood 106, 21962199.
  • 28
    Ferrucci, L., Semba, R. D., Guralnik, J. M., Ershler, W. B., Bandinelli, S., et al. (2010) Proinflammatory state, hepcidin, and anemia in older persons. Blood 115, 38103816.
  • 29
    Hashizume, M. and Mihara, M. (2011) The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis; doi: 10.1155/2011/765624.
  • 30
    van Deuren, M., Kroot, J. J. C., and Swinkels, D. W. (2009) Time-course analysis of serum hepcidin, iron and cytokines in a C282Y homozygous patient with Schnitzler's syndrome treated with IL-1 receptor antagonist. Haematologica 94, 12971300.
  • 31
    Haurani, F. I. (2006) Hepcidin and the anemia of chronic disease. Ann. Clin. Lab. Sci. 36, 36.